Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 sept. 2020 15h55 HE | Source: Intrommune Therapeutics

Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
31 août 2020 12h37 HE | Source: Bragar Eagel & Squire

AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AIMT and Encourages Investors to Contact the Firm

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
16 sept. 2019 14h25 HE | Source: Intrommune Therapeutics

Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote

New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...